Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 29; no. 15_suppl; p. TPS182
Main Authors Beer, T. M., Logothetis, C., Sharma, P., Gerritsen, W. R., Ezzeddine, R., Fairchild, J. P., Gagnier, P., Chin, K. M., Cuillerot, J.
Format Journal Article
LanguageEnglish
Published 20.05.2011
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2011.29.15_suppl.tps182